The impact of clinical risk assessment versus PAM-50 ROR score on prognosis and therapeutic decision making in patients with hormone-receptor positive early stage breast cancer

Veröffentlicht vonadmin

Devyatko, Y; Filipits, M; Greil, R; Balic, M; Bago-Horvath, Z; Singer, C; Fitzal, F; Steger, G; Gray, B; Ferree, S; Fesl, C; Soelkner, L; von Minckwitz, G; Gnant, M

View this publication in the PUBMED database